secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harmony Biosciences Holdings, Inc. (HRMY)
CIK:        0001802665
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001558370-24-000128
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harmony Biosciences reports Q4 net product revenue ~$168M, FY2023 ~$582M; 2024 guidance $700-720M
--------------------------------------------------------------------------------

- Preliminary Q4 net product revenue ~$168M, up ~31% YoY; FY2023 ~$582M, up ~33% YoY.
- Average WAKIX patients ~6,150 in Q4 2023; 2024 target ~7,000 patients.
- 2024 net product revenue guidance of $700M to $720M.
- Repurchased ~1.8M shares for $50M in Q4 2023; $150M remaining authorization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802665/000155837024000128/0001558370-24-000128-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802665/000155837024000128/hrmy-20240108x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-000128

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer